Showing 1 to 12 of 92 results
Xi and Putin's Obsession with Immortality: A Discussion on Longevity and Political Power
Russian President Vladimir Putin and Chinese President Xi Jinping discussed the possibility of extending human lifespan through biotechnology, prompting experts to comment on the feasibility and implications of such claims.
Xi and Putin's Obsession with Immortality: A Discussion on Longevity and Political Power
Russian President Vladimir Putin and Chinese President Xi Jinping discussed the possibility of extending human lifespan through biotechnology, prompting experts to comment on the feasibility and implications of such claims.
Progress
40% Bias Score
China, Russia Discuss Biotechnology and Organ Transplants at Military Parade
During Beijing's September 3, 2025 military parade, Presidents Xi Jinping and Vladimir Putin discussed biotechnology and organ transplants as potential methods for life extension, highlighting the intersection of political power and scientific advancement.
China, Russia Discuss Biotechnology and Organ Transplants at Military Parade
During Beijing's September 3, 2025 military parade, Presidents Xi Jinping and Vladimir Putin discussed biotechnology and organ transplants as potential methods for life extension, highlighting the intersection of political power and scientific advancement.
Progress
24% Bias Score
Multicolored, Brightest-Ever Glowing Plants Created
Chinese researchers created multicolored luminescent plants using strontium aluminate injection, achieving brighter glow than previous gene-edited plants and demonstrating potential for sustainable lighting, though challenges remain.
Multicolored, Brightest-Ever Glowing Plants Created
Chinese researchers created multicolored luminescent plants using strontium aluminate injection, achieving brighter glow than previous gene-edited plants and demonstrating potential for sustainable lighting, though challenges remain.
Progress
16% Bias Score
Mecklenburg-Vorpommern Funds €8.2 Million for Cell and Gene Therapy Platform
The state of Mecklenburg-Vorpommern in Germany is providing €8.2 million in funding from the European Regional Development Fund (EFRE) to support the development of a cell and gene therapy platform by a research consortium involving Miltenyi Biotec, RoweMed AG, and the University of Rostock.
Mecklenburg-Vorpommern Funds €8.2 Million for Cell and Gene Therapy Platform
The state of Mecklenburg-Vorpommern in Germany is providing €8.2 million in funding from the European Regional Development Fund (EFRE) to support the development of a cell and gene therapy platform by a research consortium involving Miltenyi Biotec, RoweMed AG, and the University of Rostock.
Progress
24% Bias Score
Engineered Bacterium Functions with Simplified Genetic Code
Researchers created Syn57, a modified E. coli bacterium functioning with 57 genetic codons instead of the standard 64, achieved by completely redesigning its genome using CRISPR-Cas9 and viral enzymes, opening new avenues in biotechnology and raising implications for environmental safety and protein...
Engineered Bacterium Functions with Simplified Genetic Code
Researchers created Syn57, a modified E. coli bacterium functioning with 57 genetic codons instead of the standard 64, achieved by completely redesigning its genome using CRISPR-Cas9 and viral enzymes, opening new avenues in biotechnology and raising implications for environmental safety and protein...
Progress
4% Bias Score
Kroma Wellness Launches Dairy-Free Colostrum Supplement
Kroma Wellness launched Super Core, the world's first dairy-free, human-optimized colostrum supplement, addressing ethical concerns and lactose intolerance issues prevalent in the $1.7 billion bovine colostrum market; it uses Effera™, a human-identical lactoferrin made via precision fermentation, cl...
Kroma Wellness Launches Dairy-Free Colostrum Supplement
Kroma Wellness launched Super Core, the world's first dairy-free, human-optimized colostrum supplement, addressing ethical concerns and lactose intolerance issues prevalent in the $1.7 billion bovine colostrum market; it uses Effera™, a human-identical lactoferrin made via precision fermentation, cl...
Progress
48% Bias Score
Biotech Expert Dispels Putin-Xi Immortality Claims, Highlights Longevity Research
Bloomberg reported a conversation between Putin and Xi about immortality, sparking global discussion; however, a biotechnologist clarifies that while longevity research is advancing rapidly, claims of readily available immortality or 150-year lifespans are currently unrealistic.
Biotech Expert Dispels Putin-Xi Immortality Claims, Highlights Longevity Research
Bloomberg reported a conversation between Putin and Xi about immortality, sparking global discussion; however, a biotechnologist clarifies that while longevity research is advancing rapidly, claims of readily available immortality or 150-year lifespans are currently unrealistic.
Progress
24% Bias Score
Putin and Xi's Remarks on Organ Transplants and Longevity Dismissed by U.S. Expert
Russian President Vladimir Putin and Chinese leader Xi Jinping's comments suggesting organ transplants could extend lifespan to 150 years have been dismissed as lacking scientific evidence by a top U.S. transplant specialist.
Putin and Xi's Remarks on Organ Transplants and Longevity Dismissed by U.S. Expert
Russian President Vladimir Putin and Chinese leader Xi Jinping's comments suggesting organ transplants could extend lifespan to 150 years have been dismissed as lacking scientific evidence by a top U.S. transplant specialist.
Progress
48% Bias Score
Canada's Biotech Sector: A Dual-Use Approach to Defence and Economic Growth
Canada's plan to increase defence spending should prioritize biotech investments to bolster national security, economic competitiveness, and global leadership in medical innovation, leveraging the dual-use nature of biotech for both defence and civilian applications.
Canada's Biotech Sector: A Dual-Use Approach to Defence and Economic Growth
Canada's plan to increase defence spending should prioritize biotech investments to bolster national security, economic competitiveness, and global leadership in medical innovation, leveraging the dual-use nature of biotech for both defence and civilian applications.
Progress
56% Bias Score
Lab-Grown Oils Offer Sustainable Alternative to Deforestation in Cosmetics Industry
Facing EU deforestation regulations and growing consumer demand for sustainable products, Paris-based SMEY uses AI to create lab-grown coconut, palm, and shea oils, aiming to provide deforestation-free, sustainable alternatives to traditional harvesting methods.
Lab-Grown Oils Offer Sustainable Alternative to Deforestation in Cosmetics Industry
Facing EU deforestation regulations and growing consumer demand for sustainable products, Paris-based SMEY uses AI to create lab-grown coconut, palm, and shea oils, aiming to provide deforestation-free, sustainable alternatives to traditional harvesting methods.
Progress
44% Bias Score
AI Designs Novel Antibiotics to Combat Drug-Resistant Bacteria
MIT scientists utilized AI to create over 36 million potential drug molecules, identifying two highly effective against gonorrhea in lab and mice studies and six others effective against other bacteria in lab settings, offering a novel approach to combat drug-resistant infections.
AI Designs Novel Antibiotics to Combat Drug-Resistant Bacteria
MIT scientists utilized AI to create over 36 million potential drug molecules, identifying two highly effective against gonorrhea in lab and mice studies and six others effective against other bacteria in lab settings, offering a novel approach to combat drug-resistant infections.
Progress
40% Bias Score
VRTX Earnings: 58% Probability of Positive One-Day Return, Trend Weakening
Vertex Pharmaceuticals (VRTX) reports earnings on August 4, 2025; over the past five years, post-earnings announcements show a 58% probability of positive one-day returns, with a median increase of 3.0%, but this trend weakens to 50% in the last three years.
VRTX Earnings: 58% Probability of Positive One-Day Return, Trend Weakening
Vertex Pharmaceuticals (VRTX) reports earnings on August 4, 2025; over the past five years, post-earnings announcements show a 58% probability of positive one-day returns, with a median increase of 3.0%, but this trend weakens to 50% in the last three years.
Progress
48% Bias Score
Showing 1 to 12 of 92 results